Recent Posts
Connect with:
Wednesday / June 26.
HomemieducationTrial Ready AMD Cases: Establishing a Registry

Trial Ready AMD Cases: Establishing a Registry

2 CPD in Australia | 0.25CD + 0.25G in New Zealand | 01 November 2018

By Professor Robyn Guymer AM and Jeena Tan The global prevalence of age related macular degeneration (AMD) continues to increase, impacting quality of life for patients, their families and carers. Early diagnosis and prompt management are essential to control the progress of this disease and minimise vision loss. Right now, a standardised classification system for AMD, new multimodal imaging techniques for diagnosis and management, and research into potential treatments are re-shaping the way this disease is diagnosed and managed.

It is hoped that a national AMD registry, that will provide the answers to remaining questions surrounding AMD, can be established, and give patients access to information and clinical trials as they become available in Australia and internationally. Read and Take Test